What the NHS pathway offers for hip arthritis

For most people diagnosed with hip arthritis, the first conversation with a GP follows a fairly predictable script — and understanding that sequence makes it easier to know where you currently sit.

The NHS pathway begins with self-management and education: understanding which activities load the hip and which protect it. Low-impact movement — swimming, cycling, and walking — is actively encouraged because it maintains muscle strength and joint mobility without the repetitive impact forces that aggravate worn cartilage. Physiotherapy builds on this by targeting the glutes and core muscles that stabilise the pelvis and take load off the joint itself; avoiding deep, low seating is a small but practical part of the same approach.

Weight management sits alongside exercise as a core pillar. Reducing body weight lowers the mechanical force transmitted through the hip with every step, which matters considerably when cartilage is already thinned.

On the pharmacological side, oral and topical NSAIDs are the standard first-line option for pain and inflammation. Walking aids — a stick used on the opposite side to the affected hip — reduce load during flare-ups, and activity modification reduces provocation without enforcing complete rest.

When those measures are insufficient, intra-articular corticosteroid (hydrocortisone) injections into the hip joint represent the established next step on the NHS before surgical referral is considered.

It is worth being clear about what this whole sequence delivers: effective symptom relief, in many cases for months at a time, but no modification of the underlying disease. Cartilage does not regrow with any of these interventions. The joint surface continues to degenerate — which matters when deciding what comes next.

Why these treatments eventually stop working well enough

The treatments outlined above work — for a time, and often for years. The issue is not their quality but their ceiling. As Kellgren-Lawrence grade advances toward III and IV, joint space narrows and load distribution across the hip becomes increasingly uneven. The same physiotherapy programme that provided meaningful relief at an earlier stage may begin to provoke pain rather than ease it — not because the exercise was wrong, but because the mechanical environment has changed.

At that point, the NHS pathway offers a clear next step: total hip arthroplasty. What it does not offer is anything in between. Current commissioning moves directly from failed conservative management to surgical listing. For patients who are not yet at listing thresholds, who are waiting on an NHS queue, or who simply prefer to delay a major operation while their function remains acceptable, that represents a real gap — not a failure of care, but a structural feature of how the pathway is currently built.

That gap can also be widened by uncertainty in guidance. Core recommendations — exercise, education, and weight management — are consistent across international guidelines. Adjuncts are not: NICE does not recommend acupuncture for hip osteoarthritis, while EULAR offers a conditional recommendation in its favour, reflecting a difference in how the same underlying evidence is interpreted. For patients searching for something further to try within conservative care, that divergence leaves the picture genuinely unclear.

The injection options in the middle ground — and their limits

Three established injection options fill part of the space between physiotherapy and surgical listing: corticosteroids, hyaluronic acid, and platelet-rich plasma (PRP). Each has genuine merit, and each has honest limits.

Corticosteroids are the most widely used and have the clearest short-term evidence. A well-placed steroid injection into the hip joint can reduce inflammation and pain meaningfully, sometimes for several months. The constraint is frequency: repeated corticosteroid injections carry a recognised risk of accelerating cartilage loss, which limits how often they can safely be given without potentially worsening the underlying problem.

Hyaluronic acid (HA) injections — viscosupplementation — work differently, lubricating joint surfaces rather than reducing inflammation. In the knee, the evidence is more established. In the hip, it is weaker. A 2006 randomised controlled trial by Qvistgaard and colleagues compared HA, corticosteroid, and saline injections directly in hip osteoarthritis and found no clear superiority for HA over saline. Subsequent cohort data remain mixed, and multiple current guidelines rate the HA evidence as weak specifically at this joint — a distinction worth making clearly, since the knee data are sometimes cited without that qualification.

PRP injections introduce biologic signalling that may reduce pain and support the joint environment. They are symptomatic in mechanism, however, rather than restorative: they do not rebuild the cartilage surface.

Across all three, a practical point applies regardless of which is chosen: hip injections delivered using landmark technique alone miss the intra-articular target 28–30% of the time. Ultrasound guidance achieves 100% placement accuracy — a patient-safety consideration, not a preference, at a joint this deeply seated.

What none of these options does is alter the joint surface structurally. For patients who have worked through them without lasting relief, that raises a reasonable question: is there an option that works at a different level altogether?

How a ChondroFiller injection works differently

ChondroFiller injection is a cell-free type I collagen hydrogel scaffold — an acellular structural matrix, not a steroid, lubricant, or anti-inflammatory agent. It contains no synthetic chemicals and no cells. What it brings to the hip joint is architecture: a dense, viscoelastic collagen structure that gels in situ once injected and sits directly over the worn articular surface.

Delivery is outpatient and image-guided throughout. Under ultrasound guidance, the scaffold is placed precisely into the focal cartilage defect on the hip articular surface. No general anaesthetic is required, there is no surgical incision, and no overnight admission is involved. The image-guidance requirement is not an optional refinement — hip injections delivered by landmark technique alone miss the intra-articular target 28–30% of the time, and a product whose effect depends on accurate intra-articular positioning needs confirmed placement, not estimated placement.

Once in position, the scaffold works at two levels. Immediately, it provides mechanical cushioning over the degenerated surface — a top-down protective layer over the defect rather than a reconstruction from beneath. Over the following 6–12 months, the patient's own progenitor cells migrate into the collagen matrix; as those cells establish repair tissue, the scaffold gradually resorbs. This is matrix-induced chondrogenesis. It is not the same as spontaneous hyaline cartilage regeneration — repair tissue, rather than original hyaline structure, occupies the defect — but published cohort data show the process produces measurable and clinically meaningful functional improvement in appropriately selected patients.

This mechanism also defines the position ChondroFiller injection occupies in the treatment pathway: it is intended for patients with focal rather than end-stage diffuse disease, sitting structurally between the palliative injection options described above and total hip replacement.

Who the ChondroFiller injection suits — and who it doesn't

The single most important suitability question is whether cartilage loss is focal or diffuse. ChondroFiller injection is designed for a contained defect — typically 2–4.5 cm² — with healthy cartilage at its borders and a joint that retains reasonable overall structure. When degeneration has become generalised across the hip (Tönnis Grade 2 or higher, with widespread joint space narrowing), the surrounding environment cannot support the repair process the scaffold depends on. In that situation, hip replacement is likely to offer more reliable long-term relief, and saying so clearly is more helpful than suggesting a preservation route unlikely to hold.

Kellgren-Lawrence Grade III/IV disease does not automatically disqualify a patient — what matters is whether the damage is concentrated or spread. A patient with a definable area of full-thickness cartilage loss and sound surrounding borders may be a strong candidate; a patient with diffuse degeneration at a similar radiological grade is not.

Age is rarely the deciding factor. Biological health, bone quality, and defect characteristics carry more weight than chronological age, and no upper age threshold is applied at assessment.

Professor Paul Y.F. Lee at Lincolnshire Hip evaluates candidacy across four dimensions: physics (how the joint is currently loaded and whether the defect has structurally sound borders), chemistry (the quality of the local joint environment), biology (the patient's capacity to mount a repair response), and timing (how far disease has progressed). A concrete illustration of how these interact: if the physics assessment reveals severe joint space collapse — Tönnis Grade 2 or higher — that finding alone typically redirects the conversation toward hip replacement, regardless of what the remaining lenses show. No single lens works in isolation; together they give a structured, honest picture of whether joint preservation is genuinely viable for that individual.

What the evidence currently shows

Across a prospective hip cohort, 17 of 21 evaluable participants — 81% — achieved good or excellent results following ChondroFiller injection, with a mean Harris Hip Score gain of approximately 33 points. A 33-point improvement on that scale is not a marginal shift; it typically represents the difference between a hip that dominates daily life and one that remains manageable. Broader European observational data pooled from suitable patients place clinical improvement rates in the 70–85% range, with MRI follow-ups showing significant defect-filling and stable matrix resorption over time.

The peer-reviewed foundation for hip-specific use includes Perez-Carro et al. (2021, PMC8322278), which describes injectable ChondroFiller as a viable approach for full-thickness acetabular cartilage defects and reports promising early functional outcomes — while explicitly noting that long-term outcome studies are still needed. That caveat is an honest summary of where the evidence stands.

No large randomised controlled trial has yet been conducted specifically for ChondroFiller injection in the hip joint. The evidence base is cohort-level: prospective, structured, and encouraging, but not the highest tier of proof. This is not a safety concern — the available data show no pattern of serious adverse events — but it does mean that the degree of certainty is proportionate to cohort rather than trial evidence. Durability beyond three to five years has not yet been established in published data.

For patients considering where ChondroFiller injection fits in their own decision-making, the picture that emerges from the current literature is of a treatment with a meaningful early signal in carefully selected candidates, delivered at a point in the disease pathway where the joint retains enough structural integrity to support a repair response. The honest position is: strong early evidence, an evidence gap at the long-term RCT level, and a clear need for continued follow-up as the technique matures.